Free Triiodothyronine as a Biomarker for Ventricular Arrhythmia Following Myocardial Infarction: A Multicenter Prospective Cohort Study.

The VA group had significantly lower FT3 levels compared to the Non-VA group in AMI patients.

• VA group FT3: 3.74 ± 0.77 pmol/L vs Non-VA group: 4.13 ± 0.81 pmol/L
• Difference was statistically significant (P < 0.001)
• 3277 consecutive patients were included with a mean age of 64.6 years
• 123 patients (3.9%) developed VA during hospitalization

FT3 level was identified as an independent predictor of ventricular arrhythmia risk in multivariate logistic regression analysis.

• Adjusted odds ratio: 0.761 (95% CI: 0.591–0.980; P = 0.035)
• Analysis was multivariate, controlling for other potential confounders
• Study was multicenter prospective cohort design across three centers from January 2018 to December 2021

A dose-dependent association was observed between FT3 levels and VA risk across quartiles.

• Progressively lower VA risks were observed across increasing FT3 quartiles
• P trend = 0.007 across quartiles
• The relationship suggests that higher FT3 levels are incrementally protective against VA

Each 1 standard deviation decrease in FT3 levels was associated with a 19.9% increased risk of ventricular arrhythmia.

• OR = 0.801 per 1 SD decrease in FT3 (95% CI: 0.651–0.984; P = 0.035)
• This corresponds to approximately a 19.9% increased VA risk per SD decrease in FT3
• Finding supports a continuous, graded relationship between FT3 and VA risk

The study enrolled 3277 consecutive AMI patients from three centers in a multicenter prospective cohort design.

• Data collected between January 2018 and December 2021
• Mean age of participants was 64.6 years
• Patients were categorized into VA (n=123, 3.9%) and Non-VA groups
• Multivariate logistic regression analyses were performed to evaluate the FT3–VA relationship